Antipsychotics for maintenance therapy of scizophrenia

16bf102fc319d621a456d9f821071253_normal.jpeg spacer.png
The Lancet
⁦‪@TheLancet‬⁩
logo_twitter-1497383721365.png
spacer_464x1-1582829598167.png
This study suggests choice of antipsychotic for maintenance treatment of adults with schizophrenia should be guided mainly by tolerability; authors report no clear differences between antipsychotics for relapse prevention. hubs.li/Q0156dN20 pic.twitter.com/2MGZz34Ven
3/1/22, 12:04 PM

Joseph (Joe) E. Thornton, M.D., DFAPA

Sublingual dexmedetomidine for treatment of agitation in bipolar disorder.

Randomized Placebo controlled trial reported in JAMA demonstrated effectiveness over placebo at 2 hours. The medication was well tolerated.
Not clear if the clinical effect is sufficient.

Preskorn SH, Zeller S, Citrome L, et al. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA. 2022;327(8):727–736. doi:10.1001/jama.2022.0799

Joseph (Joe) E. Thornton, M.D., DFAPA

Alzheimers disease like signaling in the brains of COVID-19 patients

Reiken et al from Columbia University extrapolate esoteric data from the neurochemistry of older patients with Alzheimer disease and finds similarities in this study neurocognitively impaired patients who died from COVID-19.

The main argument I find to dispel that this is simply a finding from 2 separate but very common comorbid conditions, is that the patients with COVID-19 had the pathological findings in the cerebellum which is not a location impacted by Alzheimer’s disease. They then promote their findings by stating IF this finding is true (increased activity on the ryanodine receptor) then MAYBE there is a POTENTIAL target for treatment.

Figure 4 might be of interest

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Reiken – Alzheimer s$B!>(Blike signaling in brains of COVID$B!>(B19 patients.pdf

Comorbidity of Bipolar disorder and Migraines

Mahmood T, Silverstone T. Twin concordance for bipolar disorder and migraines. Am J Psychiatry. Dec 2000;157(12):2057.

Fornaro M, Stubbs B. A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder. J Affect Disord. Jun 01 2015;178:88-97.

abstract by Fornaro …..

Joseph (Joe) E. Thornton, M.D., DFAPA

Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias | Dementia and Cognitive Impairment | JAMA Psychiatry | JAMA Network

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2789299?guestAccessKey=06dda995-fafc-4096-8201-b9854b06333b&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamapsychiatry&utm_content=olf&utm_term=021622

UT Health San Antonio, University Health perform region’s first surgery for Alzheimer’s disease – UT Hea lth San Antonio

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.